Quest for the right Drug

|
עמוד הבית / פרבנאר 20 / מידע מעלון לרופא

פרבנאר 20 PREVENAR 20 (PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19 F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-שרירי : I.M

צורת מינון:

תרחיף להזרקה : SUSPENSION FOR INJECTION

Special Warning : אזהרת שימוש

4.4   Special warnings and precautions for use

Do not inject Prevenar 20 intravascularly.
Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity

As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine.

Concurrent illness

Vaccination should be postponed in individuals suffering from acute severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

Thrombocytopenia and coagulation disorders

The vaccine must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration.


2024-0090960
The risk of bleeding in patients with coagulation disorders needs to be carefully evaluated before intramuscular administration of any vaccine, and subcutaneous administration should be considered if the potential benefit clearly outweighs the risks.

Protection against pneumococcal disease

Prevenar 20 may only protect against Streptococcus pneumoniae serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease, pneumonia or otitis media (OM). As with any vaccine, Prevenar 20 may not protect all individuals receiving the vaccine from invasive pneumococcal disease (IPD), pneumonia or OM. For the most recent epidemiological information in your country, you should consult with the relevant national organisation.

Immunocompromised individuals

Safety and immunogenicity data on Prevenar 20 are not available for individuals in immunocompromised groups. Vaccination should be considered on an individual basis.

Based on experience with pneumococcal vaccines, some individuals with altered immunocompetence may have reduced immune responses to Prevenar 20.

Individuals with impaired immune response, whether due to the use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to active immunisation. The clinical relevance of this is unknown.

Safety and immunogenicity data with Prevenar 13 (a pneumococcal conjugate vaccine consisting of 13 polysaccharide conjugates that are also in Prevenar 20) are available for individuals with HIV infection, SCD or with a HSCT (see sections 4.8 and 5.1). Prevenar 20 should be used in accordance with official recommendations.

In adults across all studied age groups, formal non-inferiority criteria were met although numerically lower geometric mean titres (GMTs) were observed with Prevenar 20 for most of the serotypes compared to Prevenar 13 (see section 5.1), , In children, numerically lower immunoglobulin G (IgG) geometric mean concentrations (GMCs) were observed for all shared serotypes compared with Prevenar 13 (see section 5.1). The clinical relevance of these observations for immunocompromised individuals are unknown.

Paediatric population

The potential risk of apnoea and the need for respiratory monitoring for 48 to 72 h should be considered when administering the primary immunisation series to very premature infants (born less than or equal to 28 weeks of gestation), and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

Excipient

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

Effects on Driving

4.7    Effects on ability to drive and use machines

Prevenar 20 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines.



2024-0090960

פרטי מסגרת הכללה בסל

התכשיר יינתן לחיסון כנגד סטרפטוקוקוס פנאומוניה במבוגרים בני 65 שנים ומעלה אשר לא עונים על הגדרות קבוצת סיכון גבוה במיוחד למחלה פנאומוקוקלית בתדריך החיסונים של משרד הבריאות.

מסגרת הכללה בסל

התוויות הכלולות במסגרת הסל

התוויה תאריך הכללה תחום קליני Class Effect מצב מחלה
התכשיר יינתן לחיסון כנגד סטרפטוקוקוס פנאומוניה במבוגרים בני 65 שנים ומעלה אשר לא עונים על הגדרות קבוצת סיכון גבוה במיוחד למחלה פנאומוקוקלית בתדריך החיסונים של משרד הבריאות. 01/02/2023 מחלות זיהומיות סטרפטוקוקוס פנאומוניה
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/02/2023
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

רישום

172 68 37443 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

07.06.23 - עלון לרופא 28.10.24 - עלון לרופא

עלון מידע לצרכן

07.06.23 - עלון לצרכן עברית 26.07.23 - עלון לצרכן אנגלית 26.07.23 - עלון לצרכן עברית 31.08.23 - עלון לצרכן ערבית 21.12.23 - עלון לצרכן אנגלית 20.12.23 - עלון לצרכן עברית 21.12.23 - עלון לצרכן ערבית 28.10.24 - עלון לצרכן עברית 28.10.24 - החמרה לעלון

לתרופה במאגר משרד הבריאות

פרבנאר 20

קישורים נוספים

RxList WebMD Drugs.com